These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8073224)

  • 1. Evaluation of 4'-iodo-4'-deoxydoxorubicin-induced cardiotoxicity in two experimental rat models.
    Podestà A; Della Torre P; Pinciroli G; Iatropoulos MJ; Brughera M; Mazué G
    Toxicol Pathol; 1994; 22(1):68-71. PubMed ID: 8073224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats.
    Della Torre P; Podesta A; Pinciroli G; Iatropoulos MJ; Mazué G
    Toxicol Pathol; 1996; 24(4):398-402. PubMed ID: 8864181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
    Working PK; Newman MS; Sullivan T; Yarrington J
    J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rat model in the comparative evaluation of anthracyclines cardiotoxicity.
    Lanza E; Rozza A; Favalli L; Monti E; Poggi P; Villani F
    Tumori; 1989 Dec; 75(6):533-6. PubMed ID: 2617699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin.
    Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M
    J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat.
    Cirillo R; Sacco G; Venturella S; Brightwell J; Giachetti A; Manzini S
    J Cardiovasc Pharmacol; 2000 Jan; 35(1):100-8. PubMed ID: 10630739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of grapeseed extract on doxorubicin-induced cardiotoxicity in rats.
    Adıyaman MŞ; Adıyaman ÖA; Dağlı AF; Karahan MZ; Kaya İ; Dağlı MN
    Herz; 2021 Apr; 46(Suppl 1):103-108. PubMed ID: 31970462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-induced late cardiotoxicity: delayed impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the rat.
    Chugun A; Temma K; Oyamada T; Suzuki N; Kamiya Y; Hara Y; Sasaki T; Kondo H; Akera T
    Can J Physiol Pharmacol; 2000 Apr; 78(4):329-38. PubMed ID: 10772060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat.
    Hirano S; Wakazono K; Agata N; Iguchi H; Tone H
    Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
    Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
    Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats.
    Mettler FP; Young DM; Ward JM
    Cancer Res; 1977 Aug; 37(8 Pt 1):2705-13. PubMed ID: 872096
    [No Abstract]   [Full Text] [Related]  

  • 12. Rat Model of Cardiotoxic Drug-Induced Cardiomyopathy.
    Nakahara T; Tanimoto T; Petrov AD; Ishikawa K; Strauss HW; Narula J
    Methods Mol Biol; 2018; 1816():221-232. PubMed ID: 29987823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin.
    Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P
    Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
    Robert J
    Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
    Della Torre P; Podestà A; Imondi AR; Moneta D; Sammartini U; Arrigoni C; Terron A; Brughera M
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):355-60. PubMed ID: 11345653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline cardiomyopathy monitored by morphologic changes.
    Billingham ME; Mason JW; Bristow MR; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):865-72. PubMed ID: 667860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
    Platel D; Pouna P; Bonoron-Adèle S; Robert J
    Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased sensitivity of neonatal rabbit sarcoplasmic reticulum to anthracycline cardiotoxicity.
    Burke BE; Mushlin PS; Cusack BJ; Olson SJ; Gambliel HA; Olson RD
    Cardiovasc Toxicol; 2002; 2(1):41-51. PubMed ID: 12189279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
    Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
    Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.